The U.S. medical weight management market was valued at USD 50 billion in 2025. This market is expected to reach USD 185 billion by 2036, growing from USD 57 billion in 2026, at a CAGR of 12.5% from 2026 to 2036, with strong volume growth partly offset by pricing pressure.

Key Highlights – U.S. Medical Weight Management Market

• The U.S. medical weight management market is expected to reach USD 185 billion by 2036, at a CAGR of 12.5% from 2026 to 2036.
• The South is the largest regional market, reflecting the region's high obesity prevalence and large population, followed by other regions.
• Anti-obesity medications, led by GLP-1 drugs, account for the overwhelming majority of the market by value.
• Retail pharmacy and telehealth are the leading distribution channels, with telehealth expanding access rapidly.
• GLP-1 drug sales reached about USD 132 billion globally in 2025, with Eli Lilly's Zepbound at USD 22.9 billion and Novo Nordisk's Wegovy at USD 18.6 billion.
• The share of U.S. adults using GLP-1 injections for weight loss rose from 5.8% to 12.4% between early 2024 and 2025, according to Gallup.
• An estimated 10 million Americans were on GLP-1 treatment in 2025, projected to reach around 25 million by 2030.
• U.S. adult obesity has declined from a peak of 39.9% in 2022 to about 36.4% in 2026, partly attributed to GLP-1 use.
• Coverage, affordability, and access, especially under Medicare and cost-conscious employers, are the primary constraints on the market.

U.S. Medical Weight Management Market: GLP-1 Medications, Rising Obesity, and Expanding Access Drive Market Growth

The U.S. medical weight management market comprises the medically supervised treatment of overweight and obesity, including anti-obesity medications, bariatric and metabolic surgery, medical devices, and physician-supervised and telehealth weight management programs. The market has been transformed over the past few years by GLP-1 medications, a class of drugs that has demonstrated substantial and sustained weight loss and has generated enormous demand, turning a long under-treated condition into one of the largest and fastest-growing markets in healthcare. It is driven by the high prevalence of obesity, the effectiveness of new medications, expanding awareness and demand, and the gradual expansion of coverage and access. According to Gallup, the share of U.S. adults using GLP-1 injections for weight loss rose from 5.8% to 12.4% in about a year, and an estimated 10 million Americans were on GLP-1 treatment in 2025, a figure projected to reach around 25 million by 2030. As access expands and new medications arrive, the market is positioned for strong continued growth, tempered by questions of cost, coverage, and durability.

GLP-1 Medications Have Transformed the Market

GLP-1 medications have fundamentally transformed the medical weight management market and are its dominant driver. These drugs, which have demonstrated substantial and sustained weight loss in clinical trials, have generated unprecedented demand: global GLP-1 sales reached about USD 132 billion in 2025, a 33.5% increase, with Eli Lilly's Zepbound reaching USD 22.9 billion and Novo Nordisk's Wegovy USD 18.6 billion in 2025, much of it in the United States. The impact extends beyond sales: the share of U.S. adults using GLP-1 injections for weight loss more than doubled to 12.4% in about a year, and U.S. adult obesity has declined from a peak of 39.9% in 2022 to about 36.4% in 2026, a shift researchers attribute partly to GLP-1 use. This transformation, from a market of limited options to one dominated by highly effective medications, is the central force shaping the market and the foundation of its growth.

High Obesity Prevalence and Large Unmet Need Drive Demand

The high prevalence of obesity and the resulting large unmet need drive demand in the market. Despite recent declines, about 36% of U.S. adults, more than 90 million people, have obesity, and many more are overweight, representing an enormous population that could benefit from medical weight management. Obesity is associated with numerous serious health conditions, including type 2 diabetes, heart disease, and others, imposing a large health and economic burden, and it has historically been under-treated, with limited effective options. The combination of a very large affected population, the serious health consequences of obesity, and the historical lack of effective treatment creates a vast unmet need that new medications and treatments are beginning to address. This large and growing addressable population, and the recognition of obesity as a treatable chronic disease, underpins the long-term demand that drives the market.

Coverage, Affordability, and Access Are the Central Variables

Coverage, affordability, and access are the central variables shaping the market's growth, more than clinical efficacy. The high price of GLP-1 medications, historically over USD 1,000 per month at list price, has made coverage and affordability the gating factor for access: Medicare has generally not covered anti-obesity medications for weight loss, and commercial and employer coverage, while expanding, remains uneven and subject to prior authorization and cost concerns. In response, manufacturers have introduced lower cash-pay prices, and the arrival of competition and oral drugs is expected to reduce costs. The trajectory of prices and coverage, including potential expansion of Medicare and employer coverage, is the single most important determinant of how many people can access treatment and therefore of the size of the market. Access and affordability, rather than demand or efficacy, are the key constraints and opportunities.

Telehealth and Digital Weight Management Expand Access

Telehealth and digital weight management are expanding access and reshaping how care is delivered. Direct-to-consumer telehealth companies, including Ro and Hims & Hers, and digital and program-based companies such as WeightWatchers, through its clinical offering, and Noom, have made it easier for consumers to access weight management medications and support, often through convenient online consultations. During periods of shortage, some provided compounded versions of the medications. These telehealth and digital channels have rapidly expanded access, particularly for consumers paying cash, and have introduced new, consumer-friendly models of care that combine medication with support. The growth of telehealth and digital weight management is a significant driver of access and a major and fast-growing channel in the market, reshaping distribution and care delivery.

Oral GLP-1s, Pipeline, and Competition Reshape the Market

The arrival of oral GLP-1 drugs, a robust pipeline, and intensifying competition are reshaping the market. The approval of the first oral GLP-1 weight-loss drug and the development of additional oral medications, which are easier to manufacture, distribute, and take than injections, are expected to dramatically expand the treated population and improve access. The pipeline is deep, with Eli Lilly and Novo Nordisk leading, and others including Amgen, Pfizer, and Viking Therapeutics developing next-generation obesity drugs, and competition is intensifying, with Lilly having gained a leading share of the U.S. market. This competition and innovation are expected to bring new options, improve outcomes, and put downward pressure on prices, expanding access. The shift toward oral drugs and the intensifying competition are key trends that will shape the size, accessibility, and structure of the market.

Bariatric Surgery and Devices Remain Important in the GLP-1 Era

Bariatric surgery and medical devices remain important components of the market, even as medications dominate. Bariatric and metabolic surgery, performed on the order of hundreds of thousands of times per year in the United States, remains the most effective treatment for severe obesity and for many patients with obesity-related conditions, providing substantial and durable results. While the rise of GLP-1 medications has affected the trajectory of surgical volumes, surgery remains essential for many patients, and there is growing interest in combining or sequencing medications and surgery. Medical devices, including gastric balloons and other technologies, provide additional options. The continued role of surgery for severe obesity, and the potential for combined approaches, means that bariatric surgery and devices remain a significant and evolving part of the market alongside the dominant medications.

Segmental Analysis

Market by Treatment Type

By treatment type, the market comprises anti-obesity medications, bariatric and metabolic surgery, medical devices, and physician-supervised programs. Anti-obesity medications, led by GLP-1 drugs, account for the overwhelming majority of the market by value, reflecting the scale of GLP-1 sales and demand, and are the fastest-growing segment. Bariatric and metabolic surgery is a significant segment, remaining the most effective treatment for severe obesity, though its trajectory is affected by the rise of medications. Medical devices, including gastric balloons, are a smaller segment, and physician-supervised and behavioral programs, often combined with medications, provide the wraparound support that improves outcomes. Medications dominate the market and drive its growth, while surgery, devices, and programs remain important, particularly for severe obesity and durable results.

Market by Distribution Channel

By distribution channel, the market spans retail pharmacy, telehealth and digital, and hospitals and clinics. Retail pharmacy is a leading channel for dispensing anti-obesity medications, while telehealth and digital channels, including direct-to-consumer telehealth and digital programs, have grown rapidly and expanded access, particularly for cash-paying consumers. Hospitals and clinics deliver bariatric surgery, medical supervision, and comprehensive weight management. Telehealth and digital channels are the fastest-growing, reshaping access and care delivery, while retail pharmacy remains central to medication distribution. The growth of telehealth, alongside traditional pharmacy and clinical channels, is reshaping the distribution structure of the market.

Market by Payer

By payer, the market includes commercial insurance, cash-pay and out-of-pocket, and government payers. Commercial and employer coverage is significant and expanding, though uneven and subject to cost concerns and prior authorization. Cash-pay and out-of-pocket spending is substantial, reflecting the many consumers who pay directly, often through telehealth, given limited coverage, and manufacturers' lower cash-pay prices. Government coverage is more limited, as Medicare has generally not covered anti-obesity medications for weight loss, though this is subject to debate and potential change, and Medicaid coverage varies by state. The balance and expansion of these payers, particularly potential Medicare and broader employer coverage, will be a key determinant of the market's growth.

Voice of Customer

Primary interviews conducted for this study consistently emphasized that demand is not the challenge; access, affordability, and durable outcomes are. Two representative perspectives are summarized below.

"The demand from our members for GLP-1s has been overwhelming, and the cost is staggering. We are trying to balance the clear clinical benefit against a price that, at scale, is unsustainable, which is why coverage decisions, prior authorization, and the arrival of cheaper oral options dominate our thinking." — Benefits director, large employer

"The bottleneck has never been demand; it has been access and affordability. As list and cash prices come down and oral drugs arrive, the market will expand dramatically, but the winners will be those who can combine the medication with the wraparound clinical support that makes weight loss durable." — Chief medical officer, telehealth weight management company

Analyst Perspective

The U.S. medical weight management market has, in the space of about three years, been utterly transformed by a single class of drugs. In our view, GLP-1 medications are not just a new product but a genuine inflection point: they have taken a condition long stigmatized and under-treated and turned it into one of the largest and fastest-growing markets in healthcare, with obesity-specific drug sales running into the tens of billions and, remarkably, beginning to move the national obesity rate. But the story is far from settled, and three questions will determine the market's ultimate size. The first is access: the drugs work, but at current prices, coverage, especially by Medicare and cost-conscious employers, is the gating factor, and the trajectory of prices and coverage matters more than clinical efficacy at this point. The second is the shift to oral drugs, which are easier to manufacture, distribute, and take, and which could dramatically expand the treated population. The third is durability, since weight tends to return when treatment stops, which points toward a large, chronic, recurring market but also raises hard questions about lifetime cost. We expect very strong growth, moderated by pricing pressure as competition intensifies, and we see a market expanding beyond a two-company drug race into a broader ecosystem of medications, telehealth, and wraparound care.

Market by Geography

South Medical Weight Management Market

The South is the largest regional market for medical weight management, reflecting the region's high obesity prevalence and large population. The South has among the highest rates of obesity in the country, with several states reporting adult obesity rates well above the national average, creating a large population that could benefit from medical weight management. The region's large and growing population, high disease burden, and the associated prevalence of obesity-related conditions such as diabetes drive substantial demand. While access and coverage vary across the region, the sheer scale of the affected population makes the South the largest regional market, and rising awareness and expanding access are driving continued growth.

Midwest Medical Weight Management Market

The Midwest is a significant regional market, with high obesity prevalence and substantial demand. Like the South, the Midwest has above-average obesity rates in many states, creating a large population in need of weight management, and the region's employers, health systems, and consumers are increasingly adopting medical weight management, including GLP-1 medications. The presence of major employers and health systems, and growing awareness and demand, drive the market. The combination of high obesity prevalence and a large population makes the Midwest an important and growing regional market for medical weight management.

West Medical Weight Management Market

The West is a significant regional market, supported by higher access and adoption in many areas. While obesity rates in parts of the West are somewhat lower than in the South and Midwest, the region's large population, higher incomes and insurance coverage in many areas, and strong adoption of telehealth and new treatments drive substantial demand. California, the most populous state, is a major market, and the region's openness to digital and telehealth care supports access to medical weight management. The combination of a large population and strong access and adoption makes the West an important market.

Northeast Medical Weight Management Market

The Northeast is a significant regional market, characterized by strong access, coverage, and adoption. The region's higher incomes, strong insurance coverage, and concentration of academic medical centers and specialists support access to medical weight management, including medications, surgery, and comprehensive programs. While obesity rates are somewhat lower than in some other regions, strong coverage and access drive significant demand and adoption. The combination of strong access and coverage and a substantial population makes the Northeast an important market for medical weight management.

Competitive Landscape

The U.S. medical weight management market is led by a small number of dominant pharmaceutical companies, alongside telehealth and digital companies, surgical and device manufacturers, and providers, in a rapidly evolving and highly dynamic landscape. Competition is dominated by the pharmaceutical companies that market GLP-1 medications, above all Eli Lilly and Novo Nordisk, alongside telehealth and digital weight management companies, bariatric surgery and device manufacturers, and healthcare providers. Participants compete on clinical efficacy and outcomes, access and affordability, brand and awareness, distribution and channel, and, increasingly, the combination of medication with support. The dominance of a few pharmaceutical companies, and the rapid entry of telehealth and other players, shape the competitive landscape.

A key competitive dynamic is the intense competition between Eli Lilly and Novo Nordisk, and the broadening of the market to include telehealth, digital, and other players. Eli Lilly, with Zepbound, and Novo Nordisk, with Wegovy, dominate the anti-obesity medication market and compete intensely, with Lilly having gained a leading U.S. share, while a deep pipeline from Amgen, Pfizer, Viking Therapeutics, and others promises further competition. Telehealth and digital companies such as Ro, Hims & Hers, WeightWatchers, and Noom compete on access and consumer experience, and surgical and device companies including Medtronic and Johnson & Johnson MedTech serve the surgical segment. Competition on innovation, access, price, and the integration of medication with support is central to the market, and its structure is evolving rapidly.

Key Players

The key companies operating in the U.S. medical weight management market include:

• Eli Lilly and Company
• Novo Nordisk A/S
• Amgen Inc.
• Pfizer Inc.
• Viking Therapeutics, Inc.
• Boehringer Ingelheim
• Currax Pharmaceuticals
• Vivus LLC
• Hims & Hers Health, Inc.
• Ro
• WeightWatchers (WW International)
• Noom, Inc.
• Found
• Omada Health
• Teladoc Health, Inc.
• Medtronic plc
• Johnson & Johnson MedTech (Ethicon)
• Boston Scientific (Apollo Endosurgery)
• Allurion Technologies
• Structure Therapeutics